Dec 11, 2024 · By Arda Ural, Ph.D. Arda Ural, Ph.D. Key innovation, technology, dealmaking and policy considerations are reshaping the industry’s future. While patent expirations of $300b will continue to put pressure on growth, robust innovation likely will partially offset top-line erosion.

Dec 23, 2024 · <p>Where are legislative trends pointing on biopharmaceutical patents? Sona De, a partner at Sidley, reviews existing proposals and offers thoughts on what&#39;s to come in 2025.</p>

Recent court rulings have changed the way branded and generic drug manufacturers should think about patent listings in the FDA Orange Book. Hatch-Waxman experts at Polsinelli detail the changes and implications, and make predictions about what comes next.

Oct 18, 2024 · By Ben Comer, Chief Editor, Life Science Leader. Stella Sarraf, Ph.D. Using small molecule drugs to restore synapses in neurological diseases. Snapshot. Los Angeles-based Spinogenix, a privately held small molecule drug discovery and development company, is currently testing two clinical candidates in four diseases: SPG302 in amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and ...

Oct 28, 2024 · <p>Explore key drugs anticipated for 2025, spanning oncology, neurology, autoimmune disorders, and infectious diseases, with potential for significant market impact and new treatment paradigms.</p>

Jan 8, 2025 · The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing number of government initiatives behind it, more investment from both public and private sectors being ...

Dec 17, 2024 · By Stuart Siedman, VP Patient Advocacy, Chiesi Global Rare Diseases. Stuart Siedman. The FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program — it’s a mouthful. And, if we don’t act now, it will sunset at the end of the year.

Nov 26, 2024 · By Ben Comer, Chief Editor, Life Science Leader. Amy Burroughs. Developing small molecules for cancer and obesity. Snapshot. What is better than first to market? Best to market, says Terns Pharmaceuticals CEO Amy Burroughs, an executive with a diverse, 25-year career in life sciences who joined Terns Pharmaceuticals as CEO in February 2024.

Oct 4, 2024 · This article is part one of a two-part series. Part two is available here.. Part 1: AI for rapid Drug Discovery. In the rapidly evolving landscape of pharmaceutical development, AI promises to revolutionize the entire drug discovery and development process, impacting target discovery, clinical trial design, site selection, and even …

Oct 3, 2024 · <p>An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment and return. However, it won&#39;t work for every company, as Abbas Kazimi, chief business officer at Nimbus Therapeutics, explains.</p>